Metabolic and cardiac adaptation to chronic pharmacologic blockade of facilitative glucose transport in murine dilated cardiomyopathy and myocardial ischemia by Heitmeier, Monique R. et al.




Metabolic and cardiac adaptation to chronic
pharmacologic blockade of facilitative glucose







See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Monique R. Heitmeier, Maria A. Payne, Carla Weinheimer, Attila Kovacs, Richard C. Hresko, Patrick Y. Jay,
and Paul W. Hruz
1SCIentIfIC REPORTs |  (2018) 8:6475  | DOI:10.1038/s41598-018-24867-1
www.nature.com/scientificreports
Metabolic and Cardiac Adaptation 
to Chronic Pharmacologic Blockade 
of Facilitative Glucose Transport in 
Murine Dilated Cardiomyopathy 
and Myocardial Ischemia
Monique R. Heitmeier1, Maria A. Payne1, Carla Weinheimer2, Attila Kovacs2, Richard C. Hresko1, 
Patrick Y. Jay1,3 & Paul W. Hruz1,4
GLUT transgenic and knockout mice have provided valuable insight into the role of facilitative glucose 
transporters (GLUTs) in cardiovascular and metabolic disease, but compensatory physiological changes 
can hinder interpretation of these models. To determine whether adaptations occur in response to 
GLUT inhibition in the failing adult heart, we chronically treated TG9 mice, a transgenic model of dilated 
cardiomyopathy and heart failure, with the GLUT inhibitor ritonavir. Glucose tolerance was significantly 
improved with chronic treatment and correlated with decreased adipose tissue retinol binding protein 
4 (RBP4) and resistin. A modest improvement in lifespan was associated with decreased cardiomyocyte 
brain natriuretic peptide (BNP) expression, a marker of heart failure severity. GLUT1 and −12 protein 
expression was significantly increased in left ventricular (LV) myocardium in ritonavir-treated animals. 
Supporting a switch from fatty acid to glucose utilization in these tissues, fatty acid transporter CD36 
and fatty acid transcriptional regulator peroxisome proliferator-activated receptor α (PPARα) mRNA 
were also decreased in LV and soleus muscle. Chronic ritonavir also increased cardiac output and dV/
dt-d in C57Bl/6 mice following ischemia-reperfusion injury. Taken together, these data demonstrate 
compensatory metabolic adaptation in response to chronic GLUT blockade as a means to evade 
deleterious changes in the failing heart.
The healthy heart hydrolyzes ~0.5 µmol/g wet weight per second of ATP for normal contractile function1. Greater 
than 70% of this ATP is generated from the oxidation of fatty acids (FA) and, to a lesser extent, utilization of other 
substrates such as carbohydrates and amino acids. In the stressed or failing heart, FA as a fuel source decreases 
and glucose, via increased glycolysis becomes a primary source of ATP production in the myocardium. Many 
patients with heart failure also suffer from insulin resistance, which further exacerbates myocardial dysfunction2. 
While it has been postulated that heart failure may lead to insulin resistance resulting in further decrease in car-
diac function3, and insulin resistance is detrimental to cardiac outcomes in patients4, the effects of altered glucose 
homeostasis on heart failure progression remains to be elucidated.
Several genetic models have been generated in an effort to determine the role of glucose homeostasis and 
metabolism on cardiac function. Glucose is transported by a family of facilitative hexose transporters known as 
GLUTs5. Of the 14 known members, the ubiquitously expressed GLUT1 and insulin-responsive GLUT4 are the 
primary glucose transporters in the heart. Mice expressing GLUT1 under the α-myosin heavy chain promoter are 
protected from pressure overload-induced heart failure6 but not high fat diet-induced cardiac dysfunction7. The 
latter is due to a failure to upregulate fatty acid oxidation in the heart and the subsequent increased cardiac fatty 
acid load results in oxidative stress. Whole body or cardiac-specific GLUT4 ablation leads to cardiac hypertrophy 
1Department of Pediatrics, Washington University School of Medicine, St. Louis, USA. 2Department of Internal 
Medicine, Washington University School of Medicine, St. Louis, USA. 3Department of Genetics, Washington 
University School of Medicine, St. Louis, USA. 4Department of Cell Biology and Physiology, Washington University 
School of Medicine, St. Louis, USA. Correspondence and requests for materials should be addressed to P.W.H. (email: 
hruz_p@kids.wustl.edu)
Received: 7 September 2017
Accepted: 11 April 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIentIfIC REPORTs |  (2018) 8:6475  | DOI:10.1038/s41598-018-24867-1
and heart failure associated with reduced fatty-acid oxidation in the heart and hyperinsulinemia8,9. GLUT8, 
and −12 protein expression is significantly increased in left ventricle of GLUT4 knockout mice10, and a ~4-fold 
increase in the expression of GLUT12 has been observed in the left ventricle of the pacing-induced canine model 
of cardiac hypertrophy11. These results implicate additional GLUTs in myocardial glucose transport. Like GLUT4, 
GLUT12 is insulin-responsive and transgenic mice overexpressing GLUT12 have improved systemic glucose tol-
erance and insulin sensitivity12. These data suggest that additional signals or expression of other GLUT isoforms 
may preserve cardiac function and have metabolic benefit. While these genetic models have provided key insights 
into mechanisms associated with cardiac dysfunction as a result of impaired glucose homeostasis, compensatory 
mechanisms may exist as the modifications are generally present at birth. Therefore, pharmacologic disruption of 
facilitative glucose transport provides an alternate means to investigate myocardial effects with the advantage that 
the timing, duration and degree of blockade can be more readily modulated.
We have extensively examined the effects of glucose transport inhibitors on whole-body glucose homeostasis 
and functional effects in insulin-responsive tissues. Specifically, we have identified HIV protease inhibitors (PIs) 
as antagonists of GLUT function through direct and reversible binding to the transporter13,14. As these drugs 
require access to the glucose binding site from the cytosolic side of the protein, they act as non-competitive 
inhibitors of glucose import15,16. Several PIs including indinavir have been shown to be selective for GLUT4 over 
GLUT1. Others like ritonavir target both GLUT1 and GLUT4. PIs have been an integral component of combined 
antiretroviral treatment (cART) regimens where they have contributed significantly to the remarkable reduction 
in HIV-associated morbidity and mortality achieved over the past two decades17. As expected, GLUT blockade 
acutely (i.e. within minutes) induces systemic insulin resistance with impaired glucose tolerance. Importantly, 
this acute effect is reversible with drug removal18. With chronic drug exposure, visceral adiposity, hyperlipidemia, 
and insulin resistance refractory to drug withdrawal are observed19. Each of these effects are known to contribute 
to the development of cardiovascular disease20. Over the last decade, several basic science and clinical studies 
have contributed to the elucidation of the molecular mechanisms that lead to PI-induced insulin resistance13,21–23. 
Since the heart, like skeletal muscle, is an insulin responsive tissue, it has been postulated that some of the adverse 
cardiac effects of PI use may be due to direct effects of glucose transport blockade.
To determine the effects of sustained glucose blockade on the development of HF in the context of periph-
eral insulin resistance and glucose intolerance, we treated TG9 mice, a rodent model of dilated cardiomyopathy 
that progresses to heart failure and death within a predictable time frame, with ritonavir to pharmacologically 
inhibit GLUTs 1 and 4. We have previously shown that acute exposure of TG9 mice to ritonavir exacerbates heart 
failure and significantly decreases lifespan24,25. These effects are associated with decreased glucose intolerance 
and increased peripheral insulin resistance due to decreased glucose uptake in skeletal muscle and heart. To 
investigate the effects of chronic GLUT blockade, ritonavir was serially administered to TG9 mice prior to the 
development of insulin resistance, glucose intolerance and dilated cardiomyopathy. We also chronically admin-
istered ritonavir to C57BL/6 mice prior to myocardial ischemia to determine the effects of GLUT inhibition on 
cardiac function in the absence of insulin resistance and glucose intolerance. We report here the effects of chronic 
inhibition of GLUTs −1 and 4- in TG9 mice on glucose homeostasis, myocardial function and survival with char-
acterization of changes in GLUT expression and mediators of insulin sensitivity. Chronic GLUT inhibition also 
did not further exacerbate the deleterious effects of ischemia reperfusion in C57BL/6 mice, but instead modestly 
improved cardiac output. Taken together, these data provide novel insight into compensatory mechanisms that 
abrogate perturbation of GLUT function. In addition to shedding light on potential effects in treated HIV infected 
patients, these data demonstrate the importance of incorporating homeostatic adaptations to targeted protein 
disruption in elucidating molecular mechanisms of disease pathogenesis.
Results
The TG9 mouse, a murine model of dilated cardiomyopathy, has proven valuable in elucidating the role of glu-
cose homeostasis on cardiac function25. This model was generated by the cardiac-specific overexpression of 
the Cre recombinase protein under the α-myosin promoter. TG9 mice develop progressive heart failure and 
predictably die within a narrow window between 11 and 13 weeks of life26. Captopril, an ACE inhibitor which 
improves heart failure survival in humans, significantly increases lifespan in these animals by 7–10 days26. We 
previously demonstrated that the acute blockade of GLUT4 by HIV protease inhibitors in 75 day old TG9 mice, 
which have signs of cardiomyopathy, causes abrupt, decompensated heart failure and death24,25. To determine 
the effects of chronic GLUT inhibition of glucose uptake on mortality, ritonavir was administered to TG9 mice 
for 4 weeks, starting at 6 weeks of age. In contrast to the mortality associated with acute administration, chronic 
ritonavir exposure resulted in a modest but significant increase in lifespan compared to vehicle-treated animals 
(80.6 ± 1.01 vs. 77.8 ± 0.61, p < 0.05, Fig. 1). mRNA levels of BNP, which correlates with heart failure severity, 
was decreased ~55% in TG9 mice treated chronically with ritonavir as compared to vehicle controls supporting 
the improvement in cardiac outcome for these mice (Fig. 2). Nuclear hormone receptor PPARα, and fatty acid 
receptor CD36 which play a critical role in FA metabolism in the heart, especially when the heart is stressed or in 
heart failure, were decreased in left ventricle of chronic ritonavir-treated animals by ~40% and ~64%, respectively 
(Fig. 2). These results demonstrate that improved survival in this animal model of heart failure is associated with 
decreased markers of fatty acid uptake and oxidation.
Ritonavir induces peripheral insulin resistance and reversible hyperglycemia in vivo when administered 
acutely13,18. Following 6 weeks of ritonavir exposure, glucose tolerance in C57Bl/6 J mice was no different than 
vehicle-treated animals (AUC 21552 ± 2000 vs. 23234 ± 1095, respectively). To determine the effects of chronic 
drug exposure on glucose tolerance and insulin sensitivity, oral glucose and insulin tolerance tests were per-
formed in TG9 animals treated with either vehicle or ritonavir. Ritonavir-treated animals exhibited improved 
glucose tolerance after 2 weeks of treatment (AUC 32482 ± 1447 vs. 27984 ± 716, p < 0.05, Fig. 3A). The effect 
persisted through treatment duration (AUC 29048 ± 1332 vs. 23322 ± 965, p < 0.05 Fig. 3B). Insulin sensitivity 
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was also improved in ritonavir-treated animals (AUC 8395 ± 1356 vs. 6519 ± 393, Fig. 4). The improvement in 
glucose tolerance and insulin sensitivity in TG9 mice correlated with a ~60% decrease in insulin resistance mark-
ers retinol-binding protein 4 (RBP4) and resistin in epidydimal fat pads isolated from ritonavir-treated animals 
(Fig. 5A). Although no difference in PPARα and CD36 mRNA levels were observed in epidydimal fat pads from 
treated and non-treated mice (Fig. 5A), a ~70% decrease in PPARα and ~50% decrease in CD36, respectively, 
was observed in soleus muscle isolated from ritonavir-treated animals vs. vehicle controls (Fig. 5B). As muscle 
Figure 1. Chronic Ritonavir Treatment Prolongs Survival in TG9 Mice. Kaplan-Meier curve of female TG9 
mice treated via intraperitoneal injection with ritonavir (10 mg/kg, n = 12) or vehicle (10% EtOH in normal 
saline, n = 10) daily starting at six weeks of age and continuing until time of death, p-value < 0.05.
Figure 2. Effects of Chronic Ritonavir Treatment on BNP, PPARα and CD36 Expression by Left Ventricle. The 
relative mRNA expression of BNP, PPARα, and CD36 in LV of 75 day old male TG9 mice, treated with vehicle 
or ritonavir since 6 weeks of age, was examined by RT-PCR as described in Methods. (n = 4–5/group). *p < 0.01 
vs. Veh, #p < 0.05 vs. Veh.
Figure 3. Chronic Ritonavir Improves Glucose Tolerance in TG9 Mice. Oral glucose tolerance test was 
performed on male TG9 mice at (A) 8 weeks of age (2 weeks treatment) and, (B) 10 weeks of age (4 weeks 
treatment) following a 5 hr fast and as described in Methods. n = 10–12/group. *p < 0.05 vs. Veh.
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is a primary glucose disposal site, contributing ~80% to glucose homeostasis, we determined whether improved 
glucose tolerance and insulin sensitivity correlated with changes in muscle GLUT expression. As shown in Fig. 6 
GLUT1 and GLUT4 were similar between vehicle and ritonavir-treated animals.These results show that improved 
glucose homeostasis in ritonavir-treated animals is associated with decreased markers of insulin resistance and 
fatty acid oxidation.
The decrease in PPARα and CD36 expression suggested a decrease in fatty acid oxidation as a source of energy, 
prompting the question whether there are concomitant changes in myocardial glucose transporters GLUTs −1, 
−4, and −12. GLUT1 and GLUT12 protein expression increased 50–70% in response to chronic ritonavir treat-
ment (Fig. 7A,C, respectively). Left ventricular GLUT4 protein expression was similar between mice treated with 
ritonavir or vehicle (Fig. 7B). These data suggest that chronic ritonavir exposure results in compensatory changes 
in GLUT protein expression to maintain (GLUT4) or increase (GLUT1and GLUT12) expression and support a 
potential switch from fatty acid oxidation to increased glucose utilization as a primary source of energy.
Ritonavir inhibits both GLUTs −1 and −416. To determine whether ritonavir inhibits GLUT12, we stably 
overexpressed human GLUT12 in HEK293 cells and decreased endogenous GLUT1 expression via shRNA 
knockdown27. The levels of other GLUTs were low or undetectable (Fig. 8A). There was a ~2.5-fold increase in 
glucose transport over control, non-transfected HEK293 cells (Fig. 8B). A dose-response experiment indicates 
that ritonavir does not specifically inhibit GLUT12-mediated glucose transport, as quantified by 2-deoxyglucose 
uptake (Fig. 8C).
To investigate whether the beneficial effects of chronic ritonavir treatment observed in TG9 mice are more 
general, we investigated the effects of chronic ritonavir treatment on cardiac function in the closed-chest 
ischemia-reperfusion (I/R) model of myocardial injury28. C57BL/6 J mice were subjected to 90 min of ischemia 
followed by 2 weeks of reperfusion while maintained on the vehicle or ritonavir chow admixture (0.1% w/w) 
for 2 weeks. Transthoracic echocardiography at the end of the 2-week reperfusion period revealed significant 
Figure 4. Effects of Chronic Ritonavir on Insulin Sensitivity in TG9 Mice. Insulin tolerance tests were 
performed following a 5 hr fast on male TG9 mice that had been treated with ritonavir or vehicle for 3 weeks as 
described in Methods. (n = 4–6/group). *p < 0.05 vs. Veh.
Figure 5. Effects of Chronic Ritonavir Treatment on Inflammation and Insulin Resistance-related Gene 
Expression by Adipose and Soleus Tissue. The relative mRNA expression of RBP4, resistin, PPARα and CD36 in 
(A) epididymal adipose, and PPARα and CD36 in (B) soleus muscle of 75 day old male TG9 mice, treated with 
vehicle or ritonavir since 6 weeks of age, was examined by RT-PCR as described in Methods. (n = 4–5/group). 
*p < 0.01 vs. Veh.
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improvement of cardiac contractile function in ritonavir-treated animals as compared to vehicle-treated con-
trols (Table 1). Cardiac output was significantly increased as was dV/dt-d, a measure of diastolic relaxation. 
Ejection fraction and systolic volume showed a trend toward improvement (p = 0.084 and 0.091 respectively). 
Consistent with the prior study by Gupta et al. where ritonavir was found to have cardioprotective against 
isoproterenol-induced myocardial necrosis29, our current results indicate that chronic ritonavir treatment does 
not impair cardiac function in mice subjected to I/R injury and even improves some parameters.
Discussion
The observed effects of chronic pharmacologic blockade of GLUT proteins in two distinct murine models of 
cardiomyopathy provide novel insight into dynamic compensatory changes in glucose transporter biology and 
the role normal glucose homeostasis in the context of heart failure. In contrast to the glucose intolerance and 
mortality observed following acute administration of ritonavir to adult TG9 mice with dilated cardiomyopathy, 
improved glucose homeostasis, insulin sensitivity and survival was observed with chronic drug exposure. This 
was accompanied by decreased mRNA levels of PPARα and CD36 in LV isolated from mice chronically treated 
Figure 6. Effects of Chronic Ritonavir Treatment on GLUT Protein Expression by Gastrocnemius Muscle. 
Protein expression of (A) GLUT1 and (B) GLUT4 were determined in 75 day old male TG9 mice, treated with 
vehicle or ritonavir since 6 weeks of age, by Western Blot analysis as described in Methods. Western blots are 
representative data for n = 6 animals/group. Representative full-length blots are presented in Supplementary 
Fig. 1. Quantitative data are normalized to GAPDH controls and are shown as means ± SEM for n = 6 animals/
group *p < 0.01 vs. Veh.
Figure 7. Effects of Chronic Ritonavir Treatment on GLUT Protein Expression by Left Ventricle. Protein 
expression of (A) GLUT1, (B) GLUT4, and (C) GLUT12 was determined in 75 day old male TG9 mice, treated 
with vehicle or ritonavir since 6 weeks of age, by Western Blot analysis as described in Methods. Western blots 
are representative data for n = 6 animals/group. Representative full-length blots are presented in Supplementary 
Fig. 1. Quantitative data are normalized to GAPDH controls and are shown as means ± SEM for n = 6 animals/
group *p < 0.01 vs. Veh, #p < 0.05 vs. Veh.
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with ritonavir. Studies by Finck et al. showed that mice expressing PPARα specifically in the heart (MHC-PPARα) 
develop cardiomyopathy and have enhanced sensitivity to ischemic insult, effects that are exacerbated when mice 
are fed a high-fat diet30. Cardiac fatty acid uptake was significantly increased in MHC-PPARα mice while reduced 
expression of genes involved in cardiac glucose utilization was associated with decreased cardiac glucose uptake31. 
In addition, MHC-PPARα mice deficient in CD36 (MHC-PPARα mice crossed to CD36−/−) fed a high fat diet 
exhibited improved cardiac function, decreased fatty acid uptake and increased GLUT4 expression with concom-
itant increases in cardiac glucose uptake32. These results suggest that PPARα and CD36 play a primary role in a 
switch from cardiac fatty acid metabolism to glucose substrate utilization that improves cardiac function. While 
we did not measure cardiac fatty acid uptake in this study, decreased cardiac expression of PPARα and CD36 
suggests a switch from fatty acid oxidation to glucose as an alternate fuel source.
In muscle, overexpression of PPARα (MCK-PPARα) causes insulin resistance, glucose intolerance and diabe-
tes in animals fed a high-fat diet33. The fatty acid receptor CD36 was increased 5.4-fold in muscle of MCK-PPARα 
mice, and the expression of GLUTs 1 and 4 fell by half, resulting in increased fatty acid and decreased glucose 
uptake. We observed similar effects but in the opposite direction in TG9 mice chronically treated with ritona-
vir: A 70% decrease in PPARα is associated with a 50% decrease in CD36 in soleus muscle. The changes, which 
were also seen in the heart, suggest reduced fatty acid uptake and oxidation in muscle. Although we did not 
observe a concomitant reduction in PPAR and CD36 in adipose tissue, we did observe reduction of the insulin 
resistance markers RBP4 and resistin in this organ. The decrease in heart and skeletal muscle is likely reflective 
of the predominant role of skeletal muscle in glucose disposal following a glucose challenge. In contrast, adi-
pose tissue accounts for a relatively minor direct role in systemic glucose uptake but functions as an important 
endocrine organ34. The net effect of these integrated changes was significantly improved lifespan, glucose tol-
erance and insulin sensitivity. Chronic ritonavir treatment may improve some aspects of cardiac function in a 
model of ischemia-reperfusion injury; it clearly did not exacerbate cardiac dysfunction. The improvements in 
TG9 mice chronically treated with ritonavir were also associated with increased GLUT1 and −12 expression in 
LV. Transgenic mice overexpressing GLUT12 have improved glucose tolerance and insulin sensitivity12; however, 
a role of GLUT12 as a basal glucose transporter in the heart rather than an insulin responsive transporter is 
Figure 8. GLUT12 OE Cell Characterization and Effects of Ritonavir on GLUT12 Activity. (A) Quantitation of 
GLUT family members in GLUT12 overexpressing was determined as described in Methods. Glucose transport 
as determined by 2-DOG uptake was determined in vehicle-treated cells (B) or in the presence of increasing 
concentrations of ritonavir (C). Data represent the mean ± S.E. of three independent measurements and in (C) 
were normalized to fit by nonlinear regression analysis using GraphPad Prism software.
Parameters Vehicle (n = 10) Ritonavir (n = 10) P-value
Heart rate (beats/min) 634 ± 9.5 664 ± 10.7 0.052
EDV (ml) 87 ± 8.9 79 ± 5.9 0.465
ESV (ml) 67 ± 8.8 56 ± 5.3 0.284
EF (%) 24 ± 2.0 30 ± 2.5 0.084
SV 20 ± 1.4 24 ± 1.3 0.091
CO 13 ± 0.8 16 ± 0.8 0.026
dV/dt-s 0.62 ± 0.04 0.69 ± 0.03 0.125
dV/dt-d 0.826 ± 0.04 1.061 ± 0.06 0.004
Table 1. Echocardiography results in closed-chest I/R mice treated chronically with ritonavir. Transthoracic 
echocardiographic images were obtained on conscious C57Bl/6 mice at 2 weeks post ischemia/reperfusion 
as described in Methods. Data are represented as the average ± SEM (n = 10/group). EDV, end-diastolic LV 
volume; ESV, end-systolic LV volume; EF, ejection fraction [(EDV–ESV)/EDV]; SV, systolic volume; CO, 
cardiac output; dV/dt-d, peak rate of LV volume increase in diastole; dV/dt-s, peak rate of LV volume decrease 
in systole.
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consistent with the role of glucose transport in cardiac function in the setting of myocardial stress35. In addition, a 
~4-fold increase in the expression of GLUT12 has been observed in the left ventricle of the pacing-induced canine 
model of cardiac hypertrophy11. The current study suggests a primary role for changes in GLUT protein and fatty 
acid-related gene expression; however, the observed beneficial effects on cardiac function and systemic glucose 
homeostasis is likely complex and may involve additional mediators such as changes in inflammatory status, 
cytokine production and redox status29,36.
While additional mechanisms likely participate in these beneficial effects the current study data are consistent 
with the acute versus chronic heart failure mouse model(s) and supporting clinical evidence. This includes the 
clinical effects observed in human patients who are exposed to ritonavir. Despite proven success in reducing viral 
load and prolonging survival, the adverse metabolic effects of PIs continue to pose significant risk to the develop-
ment of cardiovascular morbidity in the aging HIV infected population worldwide. This concern has been vali-
dated in several clinical studies37,38. Although the number of patients affected is significant, clinically recognized 
cardiovascular morbidity is seen in only a small percentage of this patient population39. Attempts to reconcile the 
apparent discrepancy between clinical prevalence of cardiac dysfunction in humans and drug-induced effects in 
the laboratory setting have included consideration of the limitations of translating data from rodent models to 
human disease40 and drug pharmacokinetics in experimental and treatment conditions41. Several other potential 
confounding factors including the effects of HIV infection itself, associated inflammation, and environmental 
influences would be predicted to increase rather than decrease cardiac morbidity. While the relatively acute effects 
of PIs on glucose homeostasis (in both humans and rodents)18,42 has aided in identifying the molecular mecha-
nism of these changes, HIV infected patients are typically treated with antiretroviral therapies chronically. Over 
time, numerous compensatory changes can occur in gene transcription, signal transduction, and metabolite con-
centrations leading to significant distal effects in target organs. Supporting this hypothesis is the observation of 
differences in measured changes in insulin sensitivity in acute versus chronic drug exposure experiments14,18,43–45. 
The observation that intermittent PI exposure is associated with increased CV risk is in agreement of the hypoth-
esis that the time of drug exposure may contribute differently to the direct cardiac effects46. Although the mech-
anism of this clinical observation is unknown, the current data suggest that intermittent glucose transport 
blockade would not allow induction of compensatory changes in the expression of GLUTs −1 and −12.
Taken together these data demonstrate that chronic pharmacologic blockade of glucose transport is linked to 
modest improvement in cardiac function and lifespan together with improvement in metabolic outcomes. This 
appears to be due in part to modulation of fatty acid oxidation and glucose utilization pathways. In addition to 
changes in facilitative glucose transporter expression, it is likely that other molecular mechanisms also participate 
in the beneficial effects observed and highlights the continued need to explore bidirectional relationships between 
systemic insulin sensitivity and cardiac function with respect to temporal sequence and magnitude of effect.
Methods
Materials. Ritonavir (Norvir) was obtained from Abbott pharmaceuticals (Abbott Park, IL). Ritonavir, in 
pure drug form and used for in vitro studies was provided by the NIH AIDS Reagent Program. GLUT1 and 
GLUT12 polyclonal antibodies were kind gifts from Mike Mueckler and Kelle Moley, respectively (Washington 
University, St. Louis, MO). GLUT4 antibody was custom produced by Invitrogen using a peptide correspond-
ing to the 16 carboxyl-terminal residues of GLUT4. Human GLUT12 plasmid was obtained from the DNASU 
Plasmid Repository (Tempe, AZ). GAPDH monoclonal antibody was purchased from Sigma (St. Louis, MO). 
Secondary anti-mouse and anti-rabbit antibodies were from LI-COR (Lincoln, NE). Unless noted, all other rea-
gents were purchased from Sigma (St. Louis, MO).
Animal Care. All mouse studies were approved by the Animal Studies Committee at Washington University 
School of Medicine and conform to the Guide for the Care and Use of Laboratory Animals published by the 
National Institute of Health. Mice were housed in the animal facility at Washington University under stand-
ard light/dark cycles and fed standard mouse chow diet and water ad libitum. The TG9 dilated cardiomyopathy 
model was developed by transgenic, high-level cardiac-specific expression of the cre recombinase protein driven 
by the α-myosin heavy chain promoter, as previously described26. The line is maintained in the FVB/N strain 
background. The characteristic development and progression of dilated cardiomyopathy in this mouse strain has 
been extensively characterized24,26. Starting at 6 weeks of age, male and female TG9 mice were given daily intra-
peritoneal (i.p.) injections of ritonavir or vehicle control (10% ethanol, 10 mg/kg body weight) until 75 days of age 
(male) or time of death (female). Female mice were used for lifespan measurements and to prevent undue stress 
on the animals for this endpoint, males were used for the glucose and insulin tolerance tests, and tissue harvest. 
Both sexes exhibit the same developmental and phenotypic characteristics of heart failure24,26. Harvested tissue 
was placed immediately in liquid nitrogen and stored at 80 °C pending further analysis. For mouse myocardial 
ischemia-reperfusion studies, eight-week-old C57BL/6 J male mice were instrumented for subsequent left ante-
rior descending (LAD) coronary artery occlusion as described47 and then randomly assigned to either a vehicle 
(powdered chow) or ritonavir (0.1% (w/w) ritonavir powdered chow admixture) group. After two weeks, animals 
were subjected to LAD occlusion for 90 minutes, followed by reperfusion and a 2 week recovery period. Animals 
were maintained on the vehicle or ritonavir chow throughout the study. Cardiac function was determined by 
echocardiography and then the animals were sacrificed and the left ventricles were dissected out and frozen for 
RNA and protein analyses.
Echocardiography. Transthoracic echocardiographic images were obtained on conscious C57Bl/6 
mice using a Vevo 2100 Imaging System (VisualSonics, Toronto, Ontario, Canada) equipped with a 30 MHz 
linear-array transducer at 2 weeks post ischemia/reperfusion. Quantification of left ventricular structure and 
function by echocardiography was done as described previously48.
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RNA isolation and PCR. Total RNA was isolated using the TrizolW Plus RNA Purification System 
(Invitrogen), and one microgram of RNA was reverse transcribed using qScript cDNA Supermix (Quanta 
Biosciences). RT-PCR and quantitation were performed in triplicate using Power SYBRW Green PCR Master Mix 
(Applied Biosystems, Foster City, CA) using the validated primers as described10. Mouse primer sequences are 
as follows: BNP FW- 5′ TCACCGCTGGGAGGTCACTC 3′, BNP RV- 5′ GTGAGGCCTTGGTCCTTCAAG 3′, 
CD36 FW- 5′ ATTGCGACATGATTAATGGCA 3′, CD36 RV- 5′ GATGGACCTGCAAATGTCAGA 3′, PPARα 
FW- 5′ CAAGGCCTCAGGGTACCACT 3′, PPARα RV- 5′ TTGCAGCTCCGATCACACTT 3′, RBP4 FW- 5′ 
ACATGGTGGGCACTTTCACAG 3′, RBP4 RV- 5′ CCAAGTTTGG AATCCCAAGCC 3′, Resistin FW- 5′ 
TGTTGTGAATTTTACTACTTGTCC 3′, Resistin RV- 5′ TGCACACGTGGTACTCAAGTG 3′ and Actin FW- 
5′ GATTACTGCTCTGGCTCCTAG 3′, Actin RV- 5′ GACTCATCGTACTCCTGCTTG 3′. To quantify GLUT 
mRNA transcript levels in the GLUT12 OE cells, qPCR was performed with standard curves generated using 
plasmids containing each human GLUT (DNASU)27.
Western Blot Analysis. Left ventricular myocardium was harvested from mice immediately following 
euthanasia and flash frozen in liquid nitrogen. Lysates were prepared by homogenizing the frozen ventricles in 
lysis buffer containing 1% Triton X-100, 0.5% NP-40, 300 mM NaCl, 20 mM Tris, pH 7.5, 2 mM EDTA, 2 mM 
EGTA, 1 mM sodium vanadate, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, and protease inhib-
itor cocktail in PBS. Lysates were incubated on ice for 30 minutes and cleared by centrifugation at 15000 × g 
for 10 minutes at 4 °C. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Pierce 
Biotechnology, Rockford, IL). Western blot analysis was then performed using 30 μg of total protein per lane. 
GLUT1, GLUT4, and GLUT12 antibodies recognizing the COOH-terminus of the transporters were used at 
a 1:1000 dilution in 5% milk in TBS-T. GAPDH was used as an internal control for loading variability. Blots 
were imaged and relative protein levels were determined using the Odyssey Infrared Imaging System Version 3.0 
(LI-COR Biosciences, Lincoln, NE).
Glucose and Insulin Tolerance Tests. Following a 5 h fast, fasting glucose level was sampled from tail vein 
(time zero); the mice received a solution of 50% dextrose (2 g/kg) via gavage (glucose tolerance test) or 0.2U/kg 
(0.02U/ml) insulin via intraperitoneal injection (insulin tolerance test). Approximately 5 ul of blood was sampled 
from tail veins at regular intervals over the following 2 h. Blood glucose was immediately determined using an 
Acenscia Contour glucometer (Bayer Health care LLC, Tarrytown, NY). OGTTs were measured at 8 and 10 weeks 
of age (2 and 4 weeks treatment, respectively), and ITT was measured at 9 weeks of age (3 weeks of treatment- to 
let the mice recover between OGTT measurements).
GLUT12 overexpressing (GLUT12 OE) cell line generation. HEK293 cells were stably transfected with human 
GLUT12 in the pcDNA 3.1(-) hygro plasmid (Life Technologies) as described previously27. Single clones were 
selected by comparing their abilities to transport radiolabeled glucose. To reduce background, native hGLUT1 
was knocked down using shRNA as described27.
Measurements of radiolabeled glucose uptake. Uptake of [3H]2-deoxy-D-glucose (2-DOG) into GLUT12 OE 
cells was measured in HEPES buffered saline at room temperature for 4 min as described previously27. Briefly, tis-
sue culture plates were pretreated with 25 μg/ml polyethyleneimine (Fluka, catalogue number P3143) in 150 mM 
NaCl for 20 min to let cells adhere. GLUT12 OE cells were plated at 400,000 cells/ml overnight. Cells were then 
washed with glucose-free HEPES buffer and starved for 30 min. The uptake of 2-DOG (50 μM) was measured in 
glucose-free HEPES buffer for 4 min at 37 °C. Non-specific uptake was measured in non-transfected HEK293 cells 
containing the shRNA GLUT1 knockdown and was subtracted from the experimental values. Data are plotted as 
specific activity or percent uptake relative to unexposed HEK293 cultures. Data were normalized to fit by nonlin-
ear regression analysis using GraphPad Prism software.
Statistical analyses. The data are reported as means ± SEM. Differences between control and experimental val-
ues were determined by two-tailed t-test, with significance determined at the P < 0.05 level.
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